- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ZEO SCIENTIFIX Aktie jetzt für 0€ handeln | |||||
| 05.10. | BODYWELLE Announces Exclusive Use of ZEO ScientifiX Biologics for Pain, Joints, and Wound Care Treatments | 409 | ACCESS Newswire | The Miami Beach practice now uses quantified stem cell and extracellular vesicle products, along with an autologous option derived from the patient's own platelets. MIAMI BEACH, FL / ACCESS Newswire... ► Artikel lesen | |
| 15.09. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.09. | Zeo ScientifiX, Inc.: ZEO ScientifiX Plans Expansion into Georgia and Tennessee as New Regenerative Medicine Laws Take Effect | 8.785 | ACCESS Newswire | Company looks to broaden its Southeast presence to support healthcare providers navigating newly enacted state laws providing for certain stem cell and regenerative medicine therapies. FORT LAUDERDALE... ► Artikel lesen | |
| 14.09. | Zeo ScientifiX, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 01.09. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.09. | Zeo ScientifiX, Inc.: ZEO ScientifiX Announces Multidisciplinary Expert Faculty Lineup for the ZEO Xperience | 322 | ACCESS Newswire | Leading physicians, scientists, regulatory experts, and healthcare innovators will convene October 23-25 at Fort Lauderdale's Pier Sixty-Six Resort + Marina for three days of regenerative medicine education... ► Artikel lesen | |
| 04.08. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.08. | Zeo ScientifiX, Inc.: ZEO ScientifiX Launches First-of-Its-Kind ZEO Xperience, a Three-Day Immersive Regenerative Medicine Experience for Healthcare Professionals | 247 | ACCESS Newswire | Hosted at Fort Lauderdale's newly reimagined Pier Sixty-Six Resort, the inaugural event combines cutting-edge biologics education, hands-on clinical training, practice growth strategies, and latest... ► Artikel lesen | |
| 24.07. | Zeo ScientifiX, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 21.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX Strengthens South Florida's Growing Biotechnology Ecosystem Through Regenerative Medicine Innovation | 348 | ACCESS Newswire | Operating from Nova Southeastern University's Center for Collaborative Research, ZEO ScientifiX is expanding physician education, scientific collaboration, and regenerative biologic innovation as Florida... ► Artikel lesen | |
| 08.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX Reports Strong Revenue Growth for Three Months and Six Months Ended April 30, 2026 | 394 | ACCESS Newswire | Company reports revenue growth of 124.6% for the quarter ended April 30, 2026 and 79.9% for the six months ended April 30, 2026, as compared to the same periods one year earlier as commercial momentum... ► Artikel lesen | |
| 01.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX to Host Live Educational Webinar for Healthcare Professionals Exploring the Southeast Regenerative Medicine Revolution | 432 | ACCESS Newswire | "One Year Later, Three States Stronger" program will examine lessons learned from Florida's first year into their pioneering stem cell law and provide physicians from other states an insight of what... ► Artikel lesen | |
| 16.06. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Zeo ScientifiX, Inc.: ZEO ScientifiX Donates Products to Support Pediatric Burn Reconstruction Mission in Peru | 277 | ACCESS Newswire | ZEO Medical Advisory Board Member Dr. Constantino Mendieta joins humanitarian effort providing reconstructive care to children recovering from severe burn injuries in Cusco, Peru DAVIE, FL / ACCESS... ► Artikel lesen | |
| 15.06. | Zeo ScientifiX, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.06. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.06. | Zeo ScientifiX, Inc.: ZEO ScientifiX Expands Medical Advisory Board with Leaders in Regenerative and Longevity Medicine | 525 | ACCESS Newswire | Company strengthens scientific leadership as regenerative medicine gains national momentum DAVIE, FL / ACCESS Newswire / June 9, 2026 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) ("ZEO ScientifiX" or the "Company")... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,820 | -0,02 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| DISC MEDICINE | 75,94 | -0,08 % | Jefferies raises Disc Medicine stock price target on drug opportunity | ||
| ENLIVEN THERAPEUTICS | 41,820 | 0,00 % | H.C. Wainwright hebt Kursziel für Enliven Therapeutics auf 73 $ an | ||
| CG ONCOLOGY | 62,24 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| TANGO THERAPEUTICS | 26,990 | +0,04 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| PRAXIS PRECISION MEDICINES | 256,86 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| ABSCI | 10,040 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| NURIX THERAPEUTICS | 26,000 | -0,08 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| SUMMIT THERAPEUTICS | 15,825 | -0,03 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 19,120 | 0,00 % | ArriVent BioPharma, Inc. - 8-K, Current Report | ||
| RAPPORT THERAPEUTICS | 25,060 | 0,00 % | Jones Trading raises Rapport Therapeutics price target on pipeline potential | ||
| ARCUS BIOSCIENCES | 19,080 | -0,03 % | Arcus Biosciences prices $250 million stock offering at $17.50 | ||
| KYMERA THERAPEUTICS | 112,56 | -0,06 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,640 | 0,00 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast |
Das Unternehmen ZEO SCIENTIFIX INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZEO SCIENTIFIX INC finden Sie auf Wallstreet Online.